



(51) International Patent Classification:  
Not classified

(21) International Application Number:  
PCT/US2022/074337

(22) International Filing Date:  
29 July 2022 (29.07.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
63/227,972 30 July 2021 (30.07.2021) US

(71) Applicant: **ARCTURUS THERAPEUTICS, INC.**  
[US/US]; 10628 Science Center Drive, Suite 250, San  
Diego, California 92121 (US).

(72) Inventors: **MATSUDA, Daiki**; c/o Arcturus Therapeu-  
tics, Inc., 10628 Science Center Drive, Suite 250, San  
Diego, California 92121 (US). **SULLIVAN, Sean Michael**;  
c/o Arcturus Therapeutics, Inc., 10628 Science Center  
Drive, Suite 250, San Diego, California 92121 (US).  
**TACHIKAWA, Kiyoshi**; c/o Arcturus Therapeutics, Inc.,  
10628 Science Center Drive, Suite 250, San Diego, Cali-  
fornia 92121 (US). **CHIVUKULA, Padmanabh**; c/o Arc-  
turus Therapeutics, Inc., 10628 Science Center Drive, Suite  
250, San Diego, California 92121 (US). **KARMALI, Priya**

**Prakash**; c/o Arcturus Therapeutics, Inc., 10628 Science  
Center Drive, Suite 250, San Diego, California 92121  
(US). **BAO, Yanjie**; c/o Arcturus Therapeutics, Inc., 10628  
Science Center Drive, Suite 250, San Diego, California  
92121 (US). **SAGI, Amit**; c/o Arcturus Therapeutics, Inc.,  
10628 Science Center Drive, Suite 250, San Diego, Califor-  
nia 92121 (US). **MUKTHAVARAM, Rajesh**; c/o Arcturus  
Therapeutics, Inc., 10628 Science Center Drive, Suite 250,  
San Diego, California 92121 (US).

(74) Agent: **REY, Gertrud U.**; MINTZ, LEVIN, COHN, FER-  
RIS, GLOVSKY AND POPEO, P.C., One Financial Cen-  
ter, Boston, Massachusetts 02111 (US).

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,  
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,  
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(54) Title: RNA VACCINES




FIG. 1A

(57) Abstract: Provided herein are RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof. Also provided herein are compositions that include RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof, and lipids. RNA molecules and compositions including them are useful for inducing immune responses.

[Continued on next page]

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*